Clinical Trial: SWOG S1900E

SWOG S1900E

A Phase II Study of Sotorasib (AMG 510) in Participants with Previously Treated Stage IV or Recurrent KRAS G12C Mutated Non-Squamous Non-Small Cell Lung Cancer (ECOG-ACRIN LUNG-MAP SUB-STUDY)
See Screening Protocol LUNGMAP

S1900E, Cohort 2  is closed to accrual effective August 15, 2024 at 12:00 pm Pacific Time.

1900E, Cohort 1 is closed to accrual effective December 13, 2023 at 12:00 p.m. PST.

LUNGMAP participants with KRASG12c and TP53 mutations and Wild Type STK11, KEAP1, NFE2L2, AND CUL3 will no longer be assigned to S1900E, effective December 13, 2023.